Rheumatoid Arthritis
Conditions
Interventions
Combination therapy of three DMARDs (bucillamine, salazosulphapyridine and methotrexate)
Combination therapy of TNF-bloking biologics and methotrexate
Sponsors
Japan Association of Rheumatologists in Private Practice
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients, fulfilled the ACR 1987 revised criteria for the classification of theumatoid arthritis 2.Patients who had disease activity (DAS28>3.2), despite of treatment with bucillamin, salazosulphapyridine, methotrexate or combination of two of them 3.Patients who had not received the treatment with biologics 4.Patients who can provide written informed concent by themselves
Exclusion criteria
Exclusion criteria: (Complication) Patients who had any of the following diagnoses or medical history: 1) Autoimmune disease except for Sjogren syndorome, and malignancy 2) Drug allergy 3) Severe heart, lung, liver. kidney and hematolodical disorders (Treatment) 4)Patient who recived intramuscular, intoravenous or epidural injection of corticosteroids within 4 weeks prior to the entry or during study 5)Patient who recived intraarticular corticosteroid at dose of over 20mg/month of prednisolone, and patients who recieved intraarticular corticosteroid at any dose within 4weeks prior to study entry or the day for observation of first end point 6)Patient who recived systemic corticosteroid with a dose of >10mg of predonisolone within 4 weeks prior to the study or during the study and Patients whose corticosteroid dose were changed within 4 weeks prior to the day for observation of first end point 7)Patient who received NSAIDs with an overdosage within 4 weeks prior to the study entry or during the study (Surgery) 8)Patient who had surgery judged to have an influence on this study by doctor 9)Patient who had the following treatment or procedure: plasma exchange, leukocyte depleted therapy or arthrocentesis against affected joint. except for the arthrocenesis following intraarticular injection of corticosteroid, within 4 weeks prior to the study entry or during the study (Others) 10)Patient who is in pregnancy, lactating, or with a possibility of the pregnancy and woman who hopes for pregnancy during study or within 1 month after the end of this study, and man who wishes his partner be pregnant during the study or within 3 months after the end of this study 11)Patient who can not go to a hospital for check-up on an appointed day 12)Patient who participated other clinical trial program within 4 months prior to the study entry (including post-marketing clinical study) 13)When principal investigator or sub investigators of this study judge the patients disqualified as a subject of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The mean of DAS28 at 6 and 12 months after initiation of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in modified Sharp Score from base-line at 12 months after initiation of treatment Percentage of patients which achieved functional remission (mHAQ<0.5) at 3, 6 and 12 months after initiation of treatment Percentage of patients which achieved clinical remission (DAS28<2.6) at 3, 6 and 12 months after initiation of treatment The mean of CDAI at 3,6 and 12 months after initiation of treatment The mean of MMP-3 at 3,6 and 12 months after initiation of treatment The cost-effectiveness at 12 months after initiation of treatment | — |
Countries
Japan
Contacts
Public ContactTsukasa Matsubara
Matsubara Mayflower Hospital Director
Outcome results
None listed